Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 22, 2009 Phil Taylor	New drug turns Alzheimer's theory on its head Researchers have been left puzzled by data showing that the antihistamine dimebolin, a drug with promising activity in improving Alzheimer's symptoms, actually seems to increase levels of the toxic protein beta amyloid.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
Chemistry World December 19, 2012 Amy Middleton-Gear	Early Alzheimer's diagnosis compound UK and US scientists have developed a labelled tracer compound that binds to plaques closely associated with Alzheimer's disease so that the plaques can be picked up by a medical imaging technique.
AskMen.com Jacob Franek	Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool January 19, 2011 Brian Orelli	High Stakes at Tomorrow's FDA Panel Meeting It's more than just Eli Lilly on the line.
Chemistry World July 20, 2012 Michael Parkin	New supramolecular Alzheimer's drugs Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer's disease, say scientists in China.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade.
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
Chemistry World October 14, 2009 Phil Taylor	Tracing amyloid in Alzheimer's A diagnostic compound that allows researchers to look into the brains of Alzheimer's patients will be used for the first time to gauge the effects of an experimental therapy for the disease.
AskMen.com Jacob Franek	Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information.
The Motley Fool October 10, 2011 Frank Vinluan	TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment.
Outside January 2010 Will Palmer	License to Swill It turns out that moderate drinking might not be preventive medicine after all. But that doesn't mean it's not good for you.
Nurse Practitioner August 2011 Davis et al.	Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
AskMen.com Kathleen Blanchard	Anti-Heart Disease Diet Cutting your risk of heart disease can be achieved with good dietary habits.
BusinessWeek September 17, 2007 Robert Parker	Sifting Through The Wines Of Chile Here are a few worthy Chilean wines.
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
Financial Planning August 1, 2009 Donna Mitchell	Alzheimer's Toll A study surveyed 369 advisors in the U.S. to gauge their understanding of Alzheimer's and their preparedness for dealing with clients who have the disease.
Chemistry World August 24, 2006 Jessica Ebert	Alzheimer's Researchers Tackle Waste Disposal The memory of mice with Alzheimer's-like symptoms is improved by inoculating the mice with an enzyme involved in protein degradation, report US researchers. The work could lead to new therapies for patients with Alzheimer's disease.
The Motley Fool September 2, 2005 Rich Duprey	An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note.
The Motley Fool April 17, 2007 Rich Duprey	Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors?
Registered Rep. August 30, 2011 Amy Burroughs	When Your Client Has Alzheimer's One early sign of the disease is trouble managing money, which puts financial advisors on the front lines.
BusinessWeek September 11, 2006 Robert Parker	Don't Tell Them It's From Washington Here are Pierre-Antoine's ratings and tasting notes on a few of the worthy wines of Washington State.
Chemistry World June 14, 2009 Hayley Birch	New technique probes Alzheimer's aggregates US and UK researchers have used a new technique to identify what they think could be the primary toxic species in the development of Alzheimer's disease
HHMI Bulletin May 2010 Lauren Gravitz	Live Long and Prosper Mix amyloid plaques with longevity and you get mice that not only live longer, but healthier too.
BusinessWeek October 2, 2006 Robert Parker	Delicious Reds At Down Under Prices The shiraz grape, known as syrah in France and California, makes for some of Australia's best red wines. But the Aussies also do a great job with cabernet sauvignon, grenache, merlot, and other reds, both as varietals and in shiraz blends.
Reactive Reports October 2007 David Bradley	How Cannabis Works What is it about the psychoactive component in marijuana, THC, or tetrahydrocannabinol, that exerts its special effects? New clues about the cannabinoid receptor type 1 have now emerged thanks to German researchers.
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
AskMen.com Joshua Levine	Is Alcohol Good For You? Some quick suggestions on how to enjoy your lifestyle and enjoy your glass of wine in order to live a healthy, long life.
AskMen.com Stephane Leung	Heart Disease Prevention Myths With heart disease still the No. 1 killer across the U.S. and Canada, readers should be wary of some of the myths related to heart disease -- such as simply being male puts you at higher risk.
The Motley Fool February 15, 2006 Rich Duprey	Eisai Eyes Alzheimer's Market Japan's Eisai Pharmaceuticals launches another challenge to Forest Labs' Alzheimer's drug. Investors, take note.
American Family Physician October 1, 2003 Vincent W. Delagarza	Pharmacologic Treatment of Alzheimer's Disease: An Update Alzheimer's disease is characterized by the development of senile plaques and neurofibrillary tangles, which are associated with neuronal destruction, particularly in cholinergic neurons. Drugs that inhibit the degradation of acetylcholine within synapses are the mainstay of therapy.
The Motley Fool August 13, 2007 Rich Duprey	U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept.
Managed Care December 2005 David S. Geldmacher	The Cost Benefit to Health Plans of Pharmacotherapy for Alzheimer's Disease As with other chronic diseases of aging, early diagnosis and pharmacologic therapy may reduce the costs for enrollees with Alzheimer's disease. This article reviews patient and caregiver outcomes associated with reduced health care costs and their implications for Managed Care Organizations.
BusinessWeek September 25, 2006 Robert Parker	The Fruits Of A Good Education Without vineyards of his own right now, David Ramey buys grapes from growers he has known for years. Here are some of his current and upcoming releases.
The Motley Fool August 27, 2007 Rich Duprey	Japan Is Serious About Alzheimer's While Britain limits access, Japan expands coverage of the top-selling treatment for Alzheimer's. Japan's regulators made the decision following a six-month study comparing Aricept with a placebo.
Nutra Solutions September 18, 2007 Kerry Hughes	Beneficial Support -- September 2007 There has been a veritable avalanche of studies citing nutritional benefits of certain foods, nutrients and herbs. This stands in contrast to the negative information that frequently emanates from the mainstream press.
Chemistry World May 21, 2013 Emma Stoye	B-vitamins may delay Alzheimer's onset UK researchers have found that high doses of B-vitamins -- including folic acid, vitamin B12 and vitamin B6 -- can slow down brain tissue atrophy, a wasting process associated with Alzheimer's disease.
AskMen.com September 7, 2001 Gregory Cartier	Wines From Around The World Let's stroll down Wine Avenue and explore some affordable and interesting wines from around the world...
BusinessWeek May 21, 2007 Robert Parker	A Yank's Mantra: Quality, Not Pedigree Jeffrey Davies works with small producers who believe in hand-harvesting and keeping quality high through low yields. Here is just a small sampling of his wines.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
BusinessWeek July 21, 2003 Amy Cortese	Wines: The Rise of the Reds As U.S. wine sales grow, reds have overtaken whites.
BusinessWeek September 4, 2006 Robert Parker	Jack Of Two Grapes, Master Of Both Philip Togni produces only two wines: a cabernet sauvignon that can last as long as a great Bordeaux; and Ca' Togni, a sweet red made from the black muscat grape.
BusinessWeek April 16, 2007 Robert Parker	Bordeaux That Will Age Gracefully Here are some terrific Bordeaux's 2003 vintages that should age well for two decades or more.